Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers
Yaoliang Tang, Cong Zhou, Qingli Li, Xiaojiao Cheng, Tinglei Huang, Fuli Li, Lina He, Baiweng Zhang, Shuiping Tu
Abstract
T-cell infiltration and activation, and a more vigorous tumor-inhibiting microenvironment. In summary, our findings highlight the therapeutic potential of combining PD-L1 blockade therapy with agonistic anti-DR5 antibody that targets MDSCs in gastric and colon cancers.
Topics & Concepts
Cancer researchImmunotherapyBlockadeMedicineMyeloid-derived Suppressor CellImmune systemTumor microenvironmentCD8Colorectal cancerCancerImmune checkpointAntibodyCancer immunotherapyT cellImmunologyReceptorSuppressorInternal medicineImmune cells in cancerCancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune Response